Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Date:9/11/2012

CRANBURY, N.J., Sept. 11, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2012. 

Fiscal Year and Recent Highlights

  • Bremelanotide development for Female Sexual Dysfunction (FSD):
  • Palatin completed patient treatment in its Phase 2B clinical trial in premenopausal women with FSD
  • Primary data analysis and announcement of top-line results anticipated in first-half of fourth quarter of calendar year 2012
  • Obesity Collaboration with AstraZeneca:
  • Multiple classes of collaboration compounds have advanced to various stages of development. Though collaboration partner AstraZeneca has decided to discontinue further development of AZD2820, the only compound in clinical trials, AstraZeneca remains committed to this collaboration program and to the continued advancement of collaboration compounds for treatment of obesity.
  • Intellectual property developments:
  • Two additional United States patents have issued in the melanocortin field
  • Palatin has advanced its bremelanotide, PL-3994, and new melanocortin peptide patent applications in countries outside the United States
  • Equity financing:
  • On July 3, 2012, Palatin closed on a $35.0 million private placement.  The offering consisted of the sale of 3,873,000 shares of common stock, Series A 2012 warrants to purchase 31,988,151 shares of common stock, and Series B 2012 warrants to purchase 35,488,380 shares of common stock.
  • Net proceeds to Palatin after deducting offering expenses were $34.5 million 
  • Fourth Quarter and Fiscal Year End 2012 ResultsPalatin reported a net loss of $5.3 million, or $(0.14) per basic and diluted share
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
    2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
    4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
    5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
    6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
    7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
    8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
    9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
    10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
    11. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2015)... ... September 01, 2015 , ... ... antibodies, announced today that the National Institutes of Health (NIH) has awarded the ... be administered by the NIH’s National Institute of Diabetes and Digestive and Kidney ...
    (Date:9/1/2015)... The Dohmen Company today announced the ... as Chief Science Officer (CSO) of Dohmen Life ... Dr. Floyd will lead Dohmen,s growing regulatory consulting ... and post approval outsourced services in quality, regulatory, ... Floyd brings decades of experience leading global regulatory ...
    (Date:9/1/2015)... ... September 01, 2015 , ... Knowledgent , the data and analytics ... advanced analytics utilizing data lakes in the healthcare industry. , As the Internet of ... of data over the last few years as more entities become technology enabled through ...
    (Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... new Director of Business Development, Asia Pacific. In this newly-created position, Gibbs will ... awareness and use of iLab’s suite of tools. This entails not only introducing ...
    Breaking Biology Technology:AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 3Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3New White Paper Explores Data Lake Opportunities in the Healthcare Industry 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3
    ... 10 Halozyme Therapeutics,Inc. (Nasdaq: HALO ), a ... today,announced that it will present at two investor conferences ... Investor Summit to be held at the,Mark Hopkins InterContinental ... 9:30 a.m. Pacific Time (12:30 p.m. Eastern Time); and, ...
    ... 10 SoluBest Ltd., a privately,held, clinical stage ... Sheckler, MBA, as CEO. Mr. Sheckler brings over ... http://www.newscom.com/cgi-bin/prnh/20080910/NEW068LOGO ), Mr. Sheckler began ... selling nutritional and pharmaceutical products. During his,time there, ...
    ... Masimo (Nasdaq:,MASI), the inventor of Pulse ... customers purchasing the Masimo Radical-7, the company,s ... Alarm as a standard feature., Conventional ... and,isolated drops in oxygen saturation values, known ...
    Cached Biology Technology:Halozyme Therapeutics to Present at Upcoming Investor Conferences 2SoluBest Appoints Michael Sheckler, MBA, as CEO 2Masimo Announces Desaturation Index 3D Alarm as Standard Feature in All Radical-7 Pulse CO-Oximetry Devices 2Masimo Announces Desaturation Index 3D Alarm as Standard Feature in All Radical-7 Pulse CO-Oximetry Devices 3
    (Date:8/19/2015)... N.Y. , Aug. 19, 2015  VOXX ... that it has entered into a Definitive Agreement ... property, of iris authentication market leader EyeLock through ... VOXX will have a controlling interest in the ... subject to completion of due diligence.  Expanding on ...
    (Date:8/12/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is proud to announce that iMedNet ... technology platform, has led the way to significant and ... 2015.   Q2 2015 and Q1 2015 were, respectively, ... value sold in the company,s 15 year history.  In ...
    (Date:8/11/2015)... GOTHENBURG, Sweden , August 11, 2015 ... sensor FPC1155. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a prominent smartphone manufacturer ... ZUK selected FPC1 155 ...
    Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
    ... life. It drives everything from photosynthesis to growth and ... light signals to control gene activity and ultimately a ... team of researchers from the Salk Institute for Biological ... gives the signal to revamp the plant,s gene expression ...
    ... For almost three decades, oceanographers have been puzzled by the ... there is very little nitrate, an essential algal nutrient. In ... Ken Johnson, along with coauthors Stephen Riser at the University ... show that mid-ocean algae obtain nitrate from deep water, as ...
    ... is part of a research team that has discovered ... giving chemists an important new tool in developing materials ... research, which is reported in the June 25 edition ... Dreyfus Professor of Chemistry at the Massachusetts Institute of ...
    Cached Biology News:Connecting the dots: How light receptors get their message across 2Connecting the dots: How light receptors get their message across 3Researchers discover source of essential nutrients for mid-ocean algae 2Researchers discover source of essential nutrients for mid-ocean algae 3UD prof helps discover new chemical method important to drug design, agrichemicals 2UD prof helps discover new chemical method important to drug design, agrichemicals 3
    ... System is ideal for developing single ... reagents. The Luminex 100 Instrument System ... version 1.7, the XY platform and ... $2000 in free Beadlyte products if ...
    Peptide-affinity Purified Polyclonal Antibody to ICEBERG Peptide with sequence EEDPQLASKMGLH, from C Terminus of the protein sequence according to NP_067546...
    A431 cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
    Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
    Biology Products: